Overview

Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy

Status:
Terminated

Trial end date:
2013-07-15

Target enrollment:

Participant gender:

Summary

This is a phase III, double-blind, randomized, multicenter, and parallel group trial with a duration of 24 weeks, followed by a 120 week Open-label Period. the primary purpose of the study is to demonstrate the efficacy of ofatumumab in reducing clinical signs and symptoms in adult RA patients after a single course of ofatumumab.

Phase:

Phase 3

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Antibodies, Monoclonal
Ofatumumab